http___www.krenizdravo.com_korisno_upute_peptoran-tablete-upute-o-koristenju_1.xml
1.1 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 21.1 22.1 23.1 24.1 25.1 26.1 27.1 28.1 29.1 30.1 31.1 32.1 33.1 33.2 33.3 33.4 33.5 33.6 33.7 33.8 33.9 33.10 33.11 34.1 35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 35.10 35.11 35.12 35.13 35.14 35.15 35.16 35.17 35.18 35.19 35.20 35.21 35.22 35.23 35.24 35.25 35.26 35.27 35.28 35.29 36.1 37.1 37.2 38.1 38.2 39.1 39.2 39.3 39.4 40.1 40.2 40.3 41.1 41.2 41.3 42.1 43.1 43.2 44.1 44.2 44.3 44.4 44.5 44.6 45.1 46.1 47.1 47.2 47.3 48.1 49.1 52.1 52.2 52.3 53.1 54.1 55.1 55.2 55.3
Zantac Tablets 150mg Last Updated on eMC 17-Mar-2014 View changes | GlaxoSmithKline UK Contact details Name of the medicinal product Qualitative and quantitative composition Pharmaceutical form Clinical particulars - 4.1 Therapeutic indications - 4.2 Posology and method of administration - 4.3 Contraindications - 4.4 Special warnings and precautions for use - 4.5 Interaction with other medicinal products and other forms of interaction - 4.6 Fertility, pregnancy and lactation - 4.7 Effects on ability to drive and use machines - 4.8 Undesirable effects - 4.9 Overdose Pharmacological properties - 5.1 Pharmacodynamic properties - 5.2 Pharmacokinetic properties - 5.3 Preclinical safety data Pharmaceutical particulars - 6.1 List of excipients - 6.2 Incompatibilities - 6.3 Shelf life - 6.4 Special precautions for storage - 6.5 Nature and contents of container - 6.6 Special precautions for disposal and other handling - Administrative data Marketing authorisation holder Marketing authorisation number(s) Date of first authorisation/renewal of the authorisation Date of revision of the text Legal status AdultsDuodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Prevention of non-steroidal anti-inflammatory drug (NSAID) (including aspirin) associated duodenal ulcers, especially in patients with a history of peptic ulcer disease. Treatment of duodenal ulcers associated with Helicobacter pylori infection. Post-operative ulcer. Oesophageal reflux disease including long term management of healed oesophagitis. Symptomatic relief in gastro-oesophageal reflux disease. Zollinger-Ellison Syndrome. Chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the above conditions. Prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patientsProphylaxis of recurrent haemorrhage with bleeding peptic ulcers. Before general anaesthesia in patients at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour. For appropriate cases, Zantac injection is also available (see separate SPC). Children (3 to 18 years)Short term treatment of peptic ulcerTreatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease. Adults (including the elderly)Usual dosage is 150 mg twice daily, taken in the morning and evening. Duodenal ulcer, gastric ulcer:The standard dosage regimen is 150 mg twice daily or 300 mg at night. It is not necessary to time the dose in relation to meals. In most cases of duodenal ulcer, benign gastric ulcer and post-operative ulcer, healing occurs within 4 weeks. Healing usually occurs after a further 4 weeks of treatment in those not fully healed after the initial course of therapy. Ulcers following NSAID therapy or associated with continued NSAIDs:8 weeks treatment may be necessaryPrevention of NSAID associated duodenal ulcers:150 mg twice daily may be given concomitantly with NSAID therapy. In duodenal ulcer, 300 mg twice daily for 4 weeks results in healing rates which are higher than those at 4 weeks with ranitidine 150 mg twice daily or 300 mg at night. The increased dose has not been associated with an increased incidence of unwanted effects. Duodenal ulcers associated with Helicobacter pylori infection:For duodenal ulcers associated with Helicobacter pylori infection, ranitidine 300 mg at bedtime or 150 mg twice daily may be given with oral amoxicillin 750 mg three times daily and metronidazole 500 mg three times daily for two weeks. Therapy with ranitidine should continue for a further two weeks. This dose regimen significantly reduces the frequency of duodenal ulcer recurrence. Maintenance treatment at a reduced dosage of 150 mg at bedtime is recommended for patients who have responded to short term therapy, particularly those with a history of recurrent ulcer. Gastro-oesophageal reflux disease:Symptom relief in gastro-oesophageal reflux disease. In patients with gastro-oesophageal reflux disease, a dose regimen of 150 mg twice daily for 2 weeks is recommended and this can be repeated in patients in whom the initial symptomatic response is inadequateOesophageal reflux disease:In the management of oesophageal reflux disease, the recommended course of treatment is either 150 mg twice daily or 300 mg at bedtime for up to 8 weeks or 12 weeks if necessary. In patients with moderate to severe oesophagitis, the dosage of ranitidine may be increased to 150 mg 4 times daily for up to 12 weeks. The increased dose has not been associated with an increased incidence of unwanted effects. Healed oesophagitis:For long term treatment, recommended adult dose is 150 mg twice daily. Long term treatment is not indicated in management of patients with unhealed oesophagitis with or without Barrett's epithelium. Zollinger-Ellison syndrome:The starting dose for Zollinger-Ellison syndrome is 150 mg three times daily, and this may be increased as necessary. Doses up to 6 grams per day have been well tolerated. Chronic episodic dyspepsia:The standard dosage regimen for patients with chronic episodic dyspepsia is 150 mg twice daily for up to 6 weeks. Anyone not responding or relapsing shortly afterwards should be investigated. Prophylaxis of haemorrhage from stress ulceration in seriously ill patients or prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration:150 mg twice daily may be substituted for the injection once oral feeding commences. Prophylaxis of acid aspiration (Mendelson's) syndrome:150 mg oral dose can be given 2 hours before anaesthesia, and preferably also 150 mg the previous evening. Alternatively, the injection is also available. In obstetric patients in labour 150 mg every 6 hours, but if general anaesthesia is required it is recommended that a non-particulate antacid (e.g. sodium citrate) be given in addition. The usual precautions to avoid acid aspiration should also be taken. Children 12 years and over For children 12 years and over the adult dosage is given. Children from 3 to 11 years and over 30 kg of weightSee Section 5.2 Pharmacokinetic Properties (Special Patient Population) Patients over 50 years of ageSee Section 5.2 Pharmacokinetic Properties (Special Patient Populations, Patients over 50 years of age) Peptic Ulcer Acute TreatmentThe recommended oral dose for the treatment of peptic ulcer in children is 4 mg/kg/day to 8 mg/kg/day administered as two divided doses to a maximum of 300 mg ranitidine per day for a duration of 4 weeks. For those patients with complete healing, another 4 weeks of therapy is indicated, as healing usually occurs after eight weeks of treatment. Gastro-Oesophageal RefluxThe recommended oral dose for the treatment of gastro-oesophageal reflux in children is 5 mg/kg/day to 10 mg/kg/day administered as two divided doses to a maximum of 600 mg (the maximum dose is likely to apply to heavier children or adolescents with severe symptoms). NeonatesSafety and efficacy in new-born patients has not been established. Renal Impairment:Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with renal impairment (creatinine clearance less than 50 ml/min). Accordingly, it is recommended that the daily dose of ranitidine in such patients should be 150 mg at night for 4-8 weeks. The same dose should be used for maintenance treatment, if necessary. If an ulcer has not healed after treatment, 150 mg twice daily dosage should be instituted followed, if need be, by maintenance treatment of 150 mg at night. Use in elderly patients:In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of ranitidine alone versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.82 (95% CI 1.26-2.64). Postmarketing data indicate reversible mental confusion, depression, and hallucinations have been reported most frequently in severely ill and elderly patients (see section 4.8). AbsorptionFollowing oral administration of 150 mg ranitidine, maximum plasma concentrations (300 to 550 ng/mL) occurred after 13 hours. Two distinct peaks or plateau in the absorption phase result from reabsorption of drug excreted into the intestine. The absolute bioavailability of ranitidine is 50-60% and plasma concentrations increase proportionally with increasing dose up to 300 mg. DistributionRanitidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142 L. MetabolismRanitidine is not extensively metabolised. The fraction of the dose recovered as metabolites is similar after both oral and i.v. dosing; and includes 6% of the dose in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1 to 2% as the furoic acid analogue. EliminationPlasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in faeces and 93% in urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in faeces and 70% in urine of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500 mL/min, which exceeds glomerular filtration indicating net renal tubular secretion. Special Patient Populations Children (3 years and above)Limited pharmacokinetic data show that there are no significant differences in half-life (range for children 3 years and above: 1.7 - 2.2 h) and plasma clearance (range for children 3 years and above: 9 - 22 ml/min/kg) between children and healthy adults receiving oral ranitidine when correction is made for body weight. Patients over 50 years of ageIn patients over 50 years of age, half-life is prolonged (3-4 h) and clearance is reduced, consistent with the age-related decline of renal function. However, systemic exposure and accumulation are 50% higher. This difference exceeds the effect of declining renal function, and indicates increased bioavailability in older patients. GlaxoSmithKline UK Stockley Park West, Uxbridge, Middlesex, UB11 1BT Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why? Active ingredients Legal categories This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.
1.1 2.1 3.1 3.2 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 20.2 21.1 21.2 21.3 22.1 22.2 23.1 24.1 25.1 26.1 27.1 28.1 29.1 30.1 31.1 32.1 33.1 34.1 35.1 36.1 37.1 37.2 38.1 39.1 40.1 41.1 42.1 42.2 43.1 44.1 45.1 46.1 46.2 47.1 48.1 48.2 48.3 49.1 50.1 51.1 51.2 52.1 53.1 54.1 55.1 56.1 57.1 57.2 57.3 58.1 59.1 59.2 60.1 61.1 61.2 62.1 63.1 63.2 64.1 65.1 66.1 66.2 66.3 67.1 68.1 68.2 69.1
Peptoran tablete – Uputa o lijeku Proizvođač: Pliva Samo na recept? DA Primjena: Antacidi, lijekovi za liječenje ulkusne bolesti, lijekovi s djelovanjem na peristaltiku Skoči na » opis » primjena » doziranje » mjere opreza » napomene Opis Sastav 1 film tableta sadržava 150 mg ranitidina u obliku klorida.* Pomoćne tvari: mikrokristalna celuloza, hipromeloza, titan dioksid (E 171). 1 film tableta sadržava 300 mg ranitidina u obliku klorida.* Pomoćne tvari: mikrokristalna celuloza, kroskarmeloza natrij, hipromeloza, titan dioksid (E 171). * aktivna supstanca GlaxoWellcome Farmaceutski oblik i veličina pakovanja film tablete; 20 film tableta po 150 mg. 10 film tableta po 300 mg. Farmakoterapijska skupina i djelovanje Peptoran je pouzdan antiulkusni lijek iz skupine antagonista H2-receptora. U propisanim dozama snažno koči bazalnu i stimuliranu sekreciju želučane kiseline te znatno smanjuje količinu želučanog soka i sadržaj pepsina. Antisekretorno djelovanje zbiva se na razini želučanih parijetalnih stanica mehanizmom selektivne blokade histaminskih H2-receptora. Terapijski učinak Peptorana započinje brzo i traje razmjerno dugo. Najviša se koncentracija u plazmi postiže dva do tri sata nakon oralne primjene. Pojedinačna doza od 150 mg uspješno koči kiselu želučanu sekreciju tijekom 12 sati. Jedna večernja doza od 300 mg dostatna je za održavanje povišene pH vrijednosti tijekom cijele noći i sljedećeg dana. Način i mjesto izdavanja Na recept Rok valjanosti Označen je na pakovanju. Lijek se ne smije rabiti nakon isteka roka valjanosti. Čuvati pri temperaturi do 25 °C. LIJEK VALJA ČUVATI IZVAN DOSEGA DJECE! Primjena Terapijske indikacije Peptoran se primjenjuje u bolesnika s ulkusom na dvanaesniku, benignim želučanim ulkusom, Zollinger-Ellisonovim sindromom, refluksnim ezofagitisom, kroničnom epizodnom dispepsijom i u ostalim stanjima s hiperaciditetom. Doziranje Ukoliko liječnik ne odredi drukčije, Peptoran se uzima prema uputi. Odrasli Peptički ulkus U liječenju akutnog ulkusa na dvanaesniku i benignoga želučanog ulkusa primjenjuje se neovisno o uzimanju obroka jedna tableta po 150 mg dvaput na dan (ujutro i navečer) ili jedna tableta po 300 mg navečer prije spavanja. Liječenje traje četiri do osam tjedana. Nakon cijeljenja ulkusa prelazi se na dozu održavanja od 150 mg na dan (prije spavanja) tijekom 12 mjeseci, uz redovite endoskopske pretrage svaka četiri mjeseca. Refluksni ezofagitis Daje se jedna tableta po 150 mg dvaput na dan ili jedna tableta po 300 mg navečer prije spavanja tijekom osam tjedana. Zollinger- Ellisonov sindrom U liječenju navedenog sindroma daje se jedna tableta po 150 mg triput na dan (ujutro, u podne i prije spavanja). Ako ustreba, doza se može povećati na 600 do 900 mg i više na dan (najviše 6 g na dan). Kronična epizodna dispepsija Daje se jedna tableta po 150 mg dvaput na dan tijekom šest tjedana. Preanestetička medikacija Bolesnicima s hipersekrecijom, za prevenciju aspiracije kiselog želučanog sadržaja tijekom operacije (Mendelsonov sindrom), dva se sata prije operacije oralno daje 150 mg Peptorana. Jedna se tableta Peptorana po 150 mg može davati po potrebi svakih 6 sati tijekom porođaja ili prije carskog reza. Djeca Peptički ulkus u djece do 16 godina liječi se s 2 do 4 mg/kg dvaput na dan. Najveća dnevna doza iznosi 300 mg. Doziranje u bolesnika s oštećenjem bubrežne funkcije Bolesnicima s ograničenom bubrežnom funkcijom, u kojih je klirens kreatinina manji od 50 ml/min, daje se 150 mg navečer prije spavanja. Predoziranje Iako je iskustvo s ranitidinom nedostatno, zbog veoma specifičnog djelovanja nakon predoziranja se ne očekuju posebni problemi, te liječenje treba biti simptomatsko i suportivno. Ako ustreba, lijek se može ukloniti iz plazme hemodijalizom. Mjere opreza Antagonisti H2-receptora mogu prikriti simptome karcinoma želuca pa prije početka liječenja želučanog ulkusa treba isključiti maligni proces. Kontraindikacije Peptoran je kontraindiciran u bolesnika preosjetljivih na ranitidin. Posebna upozorenja U bolesnika s oštećenjem bubrežne funkcije potreban je oprez. U bolesnika s ograničenom bubrežnom funkcijom dozu treba prilagoditi bubrežnom oštećenju jer se u protivnom može povećati plazmatska koncentracija lijeka. Peptoran treba izbjegavati u bolesnika s anamnezom akutne porfirije. Trudnoća i dojenje Zbog nedostatnih iskustava Peptoran se tijekom trudnoće i dojenja primjenjuje samo ako je nužno. Može se davati tijekom porođaja jer terapijske doze ne mijenjaju njegov tijek, a ni kasniji oporavak majke i novorođenčeta. Nuspojave Nuspojave Peptorana su blage, rijeke i prolazne. Moguće su glavobolja, proljev, opstipacija, vrtoglavica, pospanost, mučnina ili povraćanje, te kožni osip. Peptoran veoma rijetko može uzrokovati bradikardiju, koja nije klinički signifikantna, AV blok, te konfuziju koja je vjerojatnija u ozbiljno bolesnih osoba ili u bolesnika s bubrežnim oštećenjem. Alergijske su reakcije (uritkarija, angioedem, vrućica, bronhospazam, hipotenzija, anafilaktički šok) iznimno rijetke. Reverzibilne su hematološke promjene (leukopenija, trombocitopenija, pancitopenija, agranulocitoza) zapažene u iznimno rijetkim slučajevima, a vjerojatnije su u ozbiljno bolesnih osoba i u bolesnika liječenih lijekovima koji suprimiraju koštanu srž. O svakoj nuspojavi valja obavijestiti svog liječnika ili ljekarnika. Interakcije Ranitidin nema klinički signifikantnih interakcija. Ne djeluje na jetreni citokrom P450 i stoga ne ometa oksidativne enzimatske procese, te nema interakcija s lijekovima koji metaboliziraju tim putem. Peptoran može blago i prolazno promijeniti rezultate funkcionalnih jetrenih testova. Napomene PLIVA d.d. Ulica grada Vukovara 49, 10 000 Zagreb, Hrvatska